Nora's case begins with an unexpected pregnancy exposure. Review the product, indication, dose and timing, and arrange prompt assessment with the prescribing and pregnancy-care teams. Available studies cannot promise no risk or predict harm for an individual pregnancy. Follow the current product guidance and keep necessary metabolic care active. Before the conversation ends, confirm who owns the next step, how the patient will reach the team, and when follow-up will occur.